Overview

Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
Topical steroids are standard of care for Chronic Hand Dermatitis, but long-term use is associated with adverse effects. This study will assess the efficacy and safety of pimecrolimus cream 1% in patients with mild-to-moderate chronic hand dermatitis.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Pimecrolimus
Tacrolimus